Has Peter Gorevic, MD received payments from drug or device companies?

Yes. Drug and device makers reported $2,152 in general payments to Peter Gorevic, MD across 21 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Peter Gorevic, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Peter Gorevic, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Peter Gorevic, MD

Rheumatology · New York, NYNPI 1700899093

Payments from drug & device makers

What this record shows

Alnylam Pharmaceuticals Inc. accounts for 84.3% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2019 at $1,854 and has fallen 98.1% since, to $35 in 2025. That places this record below the midpoint for rheumatology clinicians in NY, where the typical reported total is $1,764.

$2,152in general payments, 2019–2025

Across 21 payments — averaging $102.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Alnylam Pharmaceuticals Inc.$2K
AstraZeneca$218
Akcea Therapeutics, Inc.$101
Amgen$19

$298,609in research payments, 2019–2025

Across 39 payments — averaging $7656.64 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Alnylam Pharmaceuticals Inc.$228K
Gilead$71K

What the payments were for

Travel & lodging$1,09151%
Food & beverage$1,06149%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Alnylam Pharmaceuticals Inc.	17	$1,813
AstraZeneca	2	$218
Akcea Therapeutics, Inc.	1	$101
Amgen	1	$19

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

TEGSEDI$101

How this compares

$2,152 in reported general payments places this provider in the 50th percentile of 541 rheumatology providers in New York.

See all rheumatology providers in New York →

Medicare billing

Part B allowed, 2024

$26,374

Medicare patients

Services billed

368

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other rheumatology in New York

Laurie GlimcherNew York$3.9M
Grace WrightNew York$3M
Sergio SchwartzmanNew York$2.5M
Allan GibofskyNew York$1.9M
Petros EfthimiouNew York$791K
Olga PetrynaNew York$509K
Danielle PeterselNew York$461K
Jose ScherNew York$446K
Jason FallerNew York$357K
Lindsay LallyNew York$340K

See the full list for New York →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →